Skip to main content
European Commission logo print header

Point-of-care microfluidic device for quantification of chemotherapeutic drugs in small body fluid samples by highly selective nanoparticle extraction and liquid crystal detection

Objectif

The decision-making in chemotherapy nowadays depends on standard methods that are liquid chromatography (LC-MS/MS) followed by mass spectrometry or capillary electrophoresis; both are labour- and cost-intensive and can be performed only in dedicated hospitals and laboratories. This lead to a minimal therapeutic drug monitoring in patients and hence that 30-60% of drugs are administered without clinical benefits.

We propose to develop a point-of-care device for quantification of chemotherapeutic drugs in small body fluid samples by highly selective nanoparticle extraction and liquid crystal detection incorporated in microfluidic lab-on-chip device (optofluidics based) allowing the real-time drug monitoring. This will improve the therapeutic outcome and reduced health care costs.

Appel à propositions

H2020-PHC-2014-2015

Voir d’autres projets de cet appel

Sous appel

H2020-PHC-2014-two-stage

Coordinateur

ENTE OSPEDALIERO SAVERIO DE BELLIS IRCCS
Contribution nette de l'UE
€ 293 636,40
Coût total
€ 293 636,40

Participants (10)